First quarter 2025 net sales of Qelbree ® increased 44% to $64.7 million, compared to the same period in 2024. First quarter 2025 net sales of GOCOVRI ® increased 16% to $30.7 million, compared to the ...

Supernus Pharmaceuticals Inc (SUPN) reports robust Qelbree sales and strategic advancements, despite facing increased losses ...

Q1 2025 Management View CEO Jack Khattar highlighted double-digit revenue growth from core products, excluding legacy products Trokendi XR and Oxtellar XR. These core products achieved a 26% increase ...

Supernus Pharmaceuticals, Inc. First quarter 2025 net sales of Qelbree ® increased 44% to $64.7 million, compared to the same period in 2024. First quarter 2025 net sales of GOCO ...

Supernus' reliance on Qelbree is increasing, but generic competition for other drugs poses challenges. Read why I downgrade ...

Based on Supernus Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $174.16 million and a net profit of $1 ...

Significant reduction also seen in change from baseline in daily OFF times vs placebo. HealthDay News — For patients with Parkinson disease with motor fluctuations, the oral once-daily ...

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO ...